Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer

Clinical Cancer Research

Volumn 13, Issue 5, 2007, Pages 1421-1428

  Garg, Manoj ^a   Chaurasiya, Dipak ^a   Rana, Ritu ^a   Jagadish, Nirmala ^a   Kanojia, Deepika ^a   Dudha, Namrata ^a   Kamran, Neha ^a   Salhan, Sudha ^b   Bhatnagar, Amar ^b   Suri, Sushma ^b   Gupta, Anju ^c   Suri, Anil ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b SAFDARJUNG HOSPITAL   (India)

^c Moolchand Hospital   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; SPERM ASSOCIATED ANTIGEN 9; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN SITU HYBRIDIZATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 33947357850     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2340     Document Type: Article

References (30)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Suri A. Cancer testis antigens - their importance in immunotherapy and in the early detection of cancer. Expert Opin Biol Ther 2006;6:379-89.
3. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1.
4. Tureci O, Mack U, Luxemburger U, et al. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 2006;236:64-71.
5. Nakagawa K, Noguchi Y Uenaka A, et al. XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin Cancer Res 2005;11:5496-503.
6. Iwata T, Fujita T, Hirao N, et al. Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability-positive endometrial cancer. Clin Cancer Res 2005;11:3949-57.
7. Shankar S, Mohapatra B, Suri A. Cloning of a novel human testis mRNA specifically expressed in testicular haploid germ cells, having unique palindromic sequences and encoding a leucine zipper dimerization motif. Biochem Biophys Res Commun 1998;243:561-5.
8. Jagadish N, Rana R, Selvi R, et al. Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinase-interacting protein. Biochem J 2005;389:73-82.
9. 2-terminal kinase (JNK) interacting protein exclusively expressed in testis. Keio J Med 2005;54:66-71.
10. Stone B, Schummer M, Paley RJ, et al. Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer 2003;104:73-84.
11. Willis S, Hutchins AM, Hammet F, et al. Detailed gene copy number and RNA expression analysis of the 17q12-23 region in primary breast cancers. Genes Chromosomes Cancer 2003;36:382-92.
12. Kitahara O, Katagiri T, Tsunoda T, et al. Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia 2002;4:295-303.
13. Linn SC, West RB, Pollack JR, et al. Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol 2003;163:2383-95.
14. Helm J, Enkemann SA, Coppola D, et al. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Clin Cancer Res 2005;11:2478-85.
15. Wei CL, Wu Q, Vega VB, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006;124:207-19.
16. Jagadish N, Rana R, Mishra D, Garg M, Selvi R, Suri A. Characterization of immune response in mice to plasmid DNA encoding human sperm associated antigen 9 (SPAG9). Vaccine 2006;24:3695-703.
17. Drapkin R, Hecht JL. The origins of ovarian cancer: hurdles and progress. Women's Oncol Rev 2002;2:261-8.
18. Terry KL, Sluss PM, Skates SJ, et al. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 2004;20:53-70.
19. Shankar S, Mohapatra B, Verma S, Selvi R, Jagadish N, Suri A. Isolation and characterization of a haploid germ cell specific sperm associated antigen 9 (SPAG9) from the baboon. Mol Reprod Dev 2004;69:186-93.
20. Jagadish N, Rana R, Selvi R, et al. Molecular cloning and characterization of the macaque sperm associated antigen 9 (SPAG9): an orthologue of human SPAG9 gene. Mol Reprod Dev 2005;71:58-66.
21. Straughn JM, Jr., Shaw DR, Guerrero A, et al. Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer 2004;108:805-11.
22. Tammela J, Jungbluth AA, Qian F, et al. SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Cancer Immun 2004;4:10-6.
23. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003;63:6076-83.
24. Jagadish N, Rana R, Mishra D, et al. Immunogenicity and contraceptive potential of recombinant human sperm associated antigen (SPAG9). J Reprod Immunol 2005;67:69-76.
25. Rana R, Jagadish N, Garg M, et al. Immunogenicity study of recombinant human sperm associated antigen 9 (SPAG9) in bonnet macaque (Macaca radiata). Hum Reprod 2006;21:2894-900.
26. Jager D, Stockert E, Karbach J, et al. Urine antibody against human cancer antigen NY-ESO-1. Cancer Immun 2002;2:10-8.
27. Stockert E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
28. Hasegawa K, Koizumi F, Noguchi Y, et al. SSX expression in gynecological cancers and antibody response in patients. Cancer Immun 2004;4:16.
29. Vogelstein B, Lane D, Levine A. Surfing the p53 network. Nature 2000;408:307-10.
30. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.